ONE is moving into the growth stage having proven out its tech products in a hard to enter sector (hospitals). Customers are sticky and sign long term contracts.
$0.200
Opened: 16-Mar-2026
Shares Held at Open: 7,382,258
What does ONE do?
Oneview Healthcare (ASX:ONE) is a health tech company that provides hospital networks the tools to build a virtual care and digital control centre for its patients.
ONE has developed the software that powers smart patient TVs, bedside tablets, digital whiteboards, digital door signs, virtual care, and mobile patient apps, all integrated into the hospital's clinical systems.
ONE also has a new AI-powered digital care assistant called "Ovie" designed to address the global nursing shortage.
What is the macro theme?
Nursing shortages are a systemic issue in hospital networks creating a problem for technology to solve.
Big tech companies like Google, Amazon and Microsoft are looking to enter the health tech space and companies with an early-mover advantage should thrive or become takeover targets.
We think AI will transform the standard of care in hospitals. Hospitals need to adopt AI but most don't have the internal capability to build it.
ONE is building its own AI care platform which we hope plays a role in that transformation.
Our Big Bet for ONE
"ONE re-rates to a +$500M market cap as it converts its sales pipeline into signed contracts and/or attracts a takeover bid at a premium to its market value"
NOTE: our “Big Bet” is what we HOPE the ultimate success scenario looks like for this particular Investment over the long term (3+ years). There is no guarantee that our Big Bet will ever come true. There is a lot of work to be done, many risks involved, including development risk, country risk and commodity price risk - just some of which we list in our ONE Investment Memo.
Success will require a significant amount of luck. Past performance is not an indicator of future performance.
Why did we invest in ONE?
Proven tech, liked by customers
ONE is moving into the growth stage having proven out its tech products in a hard to enter sector (hospitals). Customers are sticky and sign long term contracts.
Newly launched AI-powered care assistant (“Ovie")
ONE just launched their new AI powered ecosystem ("Ovie") which includes four products: Ovie Engage (context-aware patient prompts), Ovie Voice (language interaction), Ovie Console (real-time operational visibility for staff), and Ovie Rounds (guided experience rounding). We think ONE could be launching what might become the “Jarvis” for hospital rooms and is one of the first movers.
Nursing shortages driving demand for healthcare solutions
There is currently a 3 million global nurse shortage and in the US there are more than 260,000 nursing positions unfilled. We think ONE’s products can help alleviate this problem.
ONE is at an inflection point
We think ONE is at an inflection point for the business where it has reached “peak innovation” meaning all of the big ticket investment into hardware and software has happened and the company is now in sales/deployment mode.
Sales pipeline (180+ opportunities, 48,000+ endpoints, 156 qualified US/Canada opportunities)
ONE's sales pipeline is at an all-time high with endpoints that would be more than 3X ONE’s current installed base. A lot of the groundwork has been done building up the pipeline, now with the capital raised today ONE finally has a strong cash runway and opportunity to deliver big sales deals.
US distribution partnership with A$13BN Baxter International
Baxter is one of the world’s largest hospital suppliers and in the US they sell to more than 60% of all beds inside the US. Baxter and ONE signed a Value Added Reseller agreement where Baxter resells and co-sells ONE's platform through Baxter's existing hospital relationships. The deal has since been extended to July 2027 and expanded to include Canada.
Land and expand strategy means each hospital bed opens the door for multiple sales (endpoints)
We like ONE’s strategy of “landing” (getting one of its products/services into a hospital room) and then “expanding” by cross/up-selling its four different endpoints (TV, tablet, whiteboard, digital door sign). As a result, we think ONE can grow exponentially as it gets into new beds and add to that by upselling to existing customers.
Added to the GPO of a top-10 US hospital network
In January 2026 ONE announced it was added to the Group Purchasing Organisation (GPO) of one of the United States' ten largest health systems. This network has over 85 hospitals and over 15,000 beds. That single network is an addressable market of ~45,000 different endpoints for ONE.
Revenue growing, costs declining (thank you AI)
FY25 revenue hit €12.0 million (up 21% year-on-year). Recurring revenue reached €7.7 million (up 7%). On the cost side, cash operating expenses were down 9% in H2-2025 vs H1-2025. We think ONE is now in a position where it can really streamline the business and take advantage of the leverage that previous years investment has provided them. We also think use of AI internally can drive costs down even further.
ONE a very early adopter of AI for software development (2023)
Hospitals are notoriously hard to sell into. ONE already has plenty of sales traction AND has been going hard on using AI to develop its software since 2023. If anyone is going to get the biggest leverage from using AI coding to make products for hospitals, it's going to be a company like ONE where it has existing clients and relationships into hospitals, deep domain knowledge... AND was a VERY early adopter of AI software development.
What do we expect ONE to deliver?
Objective #1: Sales pipeline conversion into signed contracts
ONE has 180+ opportunities and 48,000+ endpoints in its sales pipeline. We want to see this translate into new signed deals, new customer logos, and accelerating endpoint growth.
Milestones
Added to GPO of top-10 US hospital network (January 2026)
First hospital wins from the Top 10 US hospital Group Purchasing Organisation network
New logo wins.
Installed beds converted into multiple “endpoints”.
Objective #2: Rollout of “Ovie” AI services
We want to see the Ovie AI product suite move from announcement to live deployment and start contributing to per-endpoint revenue uplift.
Milestones
Ovie digital care assistant unveiled
Ovie Engage launching at ViVE 2026
Ovie Voice pilot commenced (2026)
Ovie Console pilot commenced (2026)
New user experience delivered (H2 2026)
First Ovie-related revenue contribution
Objective #3: Revenue growth and path to breakeven
We want to see ONE continue its consistent growth trajectory and demonstrate a clear path to operating cash flow breakeven.
Milestones
CY2026 live deployment growth of 20% (~17,850 endpoints per guidance)
Continued decline in cash OpEx through 2026
Breakeven achieved
Objective #4: (Bonus): Strategic interest or M&A activity
This is the complete wildcard - which we don't have a base case expectation - but if ONE can show enough progress and growth then it could become an M&A target for the bigger players in the hospital room products space.
What could go wrong?
Sales / pipeline conversion risk
ONE has a large and growing pipeline, but hospital procurement cycles are long and unpredictable at typically 18 months to 2 years. Being added to a GPO (Group Purchasing Organisation) doesn't guarantee purchase orders, it just means ONE is on the approved vendor list. ONE's pipeline of hospital opportunities may take longer than expected to convert into signed contracts, or may not convert at all. We see this is the single biggest risk to our investment thesis.
Baxter dependency risk
A key part of ONE's US strategy relies on Baxter's salesforce co-selling and reselling ONE's products. If Baxter moves slowly, reprioritises, or if the partnership doesn't deliver the volume of introductions we hope for, this could materially slow ONE's US growth. The Baxter-led pipeline is beyond ONE's direct control.
Funding risk / dilution risk
ONE had €4.6 million in cash at 31 December 2025 and has been consuming approximately €1.4 million per quarter in net operating cash outflows. Growth companies need cash to achieve their goals. ONE has raised $19M (plus has a planned $2M Share Purchase Plan for existing holders) to extend its cash runway, but if the company doesn't convert pipeline into revenue at the pace needed, further capital raises may be required, which would dilute existing shareholders. ONE has raised capital multiple times since listing in 2016.
Market risk
Tech stocks could fall in value again. Even if ONE does everything right from an operational standpoint, the market could always sell off or favour different sectors. ONE is a small-cap health tech stock and is subject to broader market sentiment.
Other Risks
Like any small-cap technology company operating in the healthcare sector, ONE carries significant risk, here we aim to identify a few more risks.
ONE’s technology must integrate seamlessly with complex, legacy hospital IT systems, including Electronic Health Records (EHR) and building management software. There is a high implementation risk that deploying these systems across large hospital networks takes much longer and costs more than anticipated, which can delay revenue recognition and frustrate clients.
The company also handles highly sensitive patient information and operates in a strictly regulated environment, primarily governed by HIPAA laws in the United States. Any data breach, cyberattack, or failure to comply with these stringent privacy regulations could lead to severe financial penalties, lawsuits, and irreversible reputational damage that would cripple the business.
While ONE’s new AI-powered care assistant, "Ovie," presents a significant growth opportunity, it also introduces new technology and adoption risks. There is no guarantee that overworked hospital staff or patients will actually adopt and use the new AI tools, or that the AI will perform flawlessly in a high-stakes clinical environment where software errors can have serious consequences.
Furthermore, hospital budgets are notoriously tight and heavily dependent on government reimbursement rates and private insurance payouts. If macro-economic conditions worsen, or if healthcare funding is cut, hospitals may freeze capital expenditure, causing ONE's target customers to delay or cancel their planned digital upgrades.
Investors should consider these risks carefully and seek professional advice tailored to their personal circumstances before investing.
What is our investment plan?
We plan to hold a position in ONE for the next 3-5 years (and beyond) as it progresses its plan to gain significant market penetration in the lucrative US healthcare market, and (as always) may look to take some profit by selling up to ~20% of our holding if the company successfully delivers on the key objectives listed above and the share price hopefully re-rates again.
Disclosure: Disclosure: S3 Consortium Pty Ltd (the Company) and Associated Entities own 7,382,258 ONE Shares at the time of publishing this Investment Memo. The Company has been engaged by ONE to share our commentary on the progress of our Investment in ONE over time. This information is general in nature about a speculative investment and does not constitute personal advice. It does not consider your objectives, financial situation, or needs. Any forward-looking statements are uncertain and not a guaranteed outcome.
Opened: 22-Sep-2023
Closed: 16-Mar-2026
Shares Held at Open: 8,818,333
Shares Held at Close: 7,382,258
Reason Memo Closed: New Memo Initiated
What does ONE do?
Oneview Healthcare (ASX:ONE) is a health tech company that provides hospital patients a “virtual care and digital control centre” at their bedside.
ONE’s products are cloud-hosted patient dashboards that help make hospitals more efficient and patients more engaged in their own care.
What is the macro theme?
Nursing shortages brought on by the pandemic highlighted the systemic issues in healthcare systems. The trend now is for these institutions to modernise by adopting new healthcare technology.
Big tech companies like Google, Amazon and Microsoft are looking to enter the health tech space and companies with an early-mover advantage should thrive or become takeover targets in their own right.
[Memo Assessment - 16-Mar-2026]: Grade = A
Our Big Bet for ONE
"ONE re-rates to a +$500M market cap as it converts its sales pipeline into signed contracts and/or attracts a takeover bid at a premium to its market value"
NOTE: our “Big Bet” is what we HOPE the ultimate success scenario looks like for this particular Investment over the long term (3+ years). There is no guarantee that our Big Bet will ever come true. There is a lot of work to be done, many risks involved, including development risk, country risk and commodity price risk - just some of which we list in our ONE Investment Memo.
Success will require a significant amount of luck. Past performance is not an indicator of future performance.
Why did we invest in ONE?
Proven tech, liked by customers
ONE is moving into the growth stage having proven out its tech products in a hard to enter sector (hospitals). Customers are sticky and sign long term contracts.
[Memo Assessment - 16-Mar-2026]: Grade = A
Value Added Reseller agreement with largest hospital bed supplier in US
ONE now has an initial 2 year “value added reseller agreement” with the largest hospital bed supplier in the US (Baxter International).
Under the agreement, Baxter will sell ONE’s technology to certain customers in Baxters’ current customer base (~75% of the US hospital bed market). Given the market reach of Baxter, this agreement could unlock significant growth in contracted beds for ONE.
[Memo Assessment - 16-Mar-2026]: Grade = A
Well funded to grow further
ONE completed a $20M placement in July 2023 that should provide the company with the funds it needs to become a sustainable operating cashflow positive business and further penetrate the US healthcare market.
[Memo Assessment - 16-Mar-2026]: Grade = A
Potential faster growth from “bring your own device” (“BYOD”) solution
ONE is developing a platform for patients to use their own phone or tablet.
This upgrade in ONE’s tech could remove the hardware costs associated with setting up ONE in a hospital potentially increasing ONE’s margins, reducing how long it takes for ONE to close a deal - and most importantly, helping hospitals more rapidly improve the patient experience.
[Memo Assessment - 16-Mar-2026]: Grade = A
Nursing shortages driving demand for healthcare solutions
Since the pandemic nursing shortages in Australia and the US have worsened.
These shortages put pressure on healthcare systems which causes more stress and ‘burnout’ for existing nurses.
Due to these issues, hospitals are now looking for technology to better improve their healthcare service and reduce the burden on nursing staff.
Although hospitals are notorious technology laggards, we think that the nursing crisis will be the impetus that drives change in these institutions and improves the healthcare system overall.
[Memo Assessment - 16-Mar-2026]: Grade = A
What do we expect ONE to deliver?
Objective #1: Repeat sales success and hit 25,000 beds
For ONE, ‘contracted beds’ is like an ‘active user’ metric for a tech company. We think this is the basis for judging ONE’s success.
More contracted beds = more revenue.
Building on ONE’s previous 15,000 bed achievement, we want to see ONE hit a total of 25,000 in CY2024, primarily out of the USA.
ONE is projecting growth of 20-25% across this metric in FY23 excluding the potential beds from the Baxter agreement and BYOD solution.
[Memo Assessment - 16-Mar-2026]: Grade = A
Objective #2: More deals with major hospital networks through Baxter agreement
We want to see ONE sign more deals with more hospitals.
Given Baxter’s large share of the US hospital bed market - we think Baxter is the ideal partner for ONE to achieve this goal.
Baxter can introduce ONE’s products to major US hospital networks that already have Baxter’s products.
The Baxter value added reseller agreement has started and the market launch is expected in Q3 CY2023, and we are hoping to see sales traction from this agreement in Q1 CY2024.
[Memo Assessment - 16-Mar-2026]: Grade = A
Objective #3: More progress on BYOD solution
With sales and marketing activities already commenced for the BYOD solution, we expect the product to become available in Q1 CY2024.
This includes the launch of the product through a pilot program in the US with an existing US hospital customer - NYU Langone.
If the pilot program is agreed and is successful, we’d want to see ONE expand the program to eventually capture a large potential market in the US and other key markets.
[Memo Assessment - 16-Mar-2026]: Grade = A
What could go wrong?
Sales risk
Despite a strong customer retention rate and the endorsement of the product by prestigious hospitals, ONE could lose key clients or not seal as many deals, hurting their revenue and share price.
Large institutions like hospitals don’t tend to adopt new technology very often and the sales cycle can be long. This feature of ONE’s customer base can cause delays in sales that drag out over a long time,
Marco factors in the market including a recession can cause a reduction in spending on new technology, affecting ONE’s ability to make sales.
[Memo Assessment - 16-Mar-2026]: Grade = A
Distribution partner risk
A key part of ONE’s strategy is to sell its products through a distribution partner like Baxter, Microsoft or Samsung.
Although ONE has a strong relationship with these companies, if they move slowly - or don’t prioritise ONE’s products when making a sale - then it could reduce the sales outcomes for ONE.
[Memo Assessment - 16-Mar-2026]: Grade = A
Funding risk
Although ONE raised $20M in July 2023, growth companies need cash to achieve their goals. If ONE doesn’t use the money from this raise wisely, then share price pain could follow. This was ONE’s fourth capital raise since it listed in 2016.
[Memo Assessment - 16-Mar-2026]: Grade = A
Technology risk
ONE will need to add functionality to its products over time as the health tech industry advances. The BYOD rollout may not go as planned.
Also, ONE has flagged that a range of additional features are in the pipeline, and the successful roll out of these features could help it reduce this particular risk as hospitals become more advanced.
[Memo Assessment - 16-Mar-2026]: Grade = A
Market risk
Tech stocks could fall in value again. Even if ONE does everything right from an operational standpoint, the market could always sell off or favour different sectors.
[Memo Assessment - 16-Mar-2026]: Grade = A
What is our investment plan?
We plan to hold a position in ONE for the next 3-5 years (and beyond) as it progresses its plan to gain significant market penetration in the lucrative US healthcare market, and (as always) may look to take some profit by selling up to ~20% of our holding if the company successfully delivers on the key objectives listed above and the share price hopefully re-rates again.
[Memo Assessment - 16-Mar-2026]: Grade = A
Disclosure: Disclosure: S3 Consortium Pty Ltd (The Company) and Associated Entities own 8,818,333 ONE shares at the time of publishing this memo. The Company has been engaged by ONE to share our commentary on the progress of our Investment in ONE over time.
Opened: 13-Jan-2022
Closed: 22-Sep-2023
Shares Held at Open: 8,525,000
Shares Held at Close: 8,818,333
Reason Memo Closed: Sales Objective Acheived
What does ONE do?
Oneview Healthcare (ASX:ONE) is a health tech company that provides hospital patients a “virtual care and digital control centre” at their bedside. ONE’s products are cloud-hosted patient dashboards that help make hospitals more efficient and patients more engaged in their own care.
What is the macro theme?
The pandemic has rapidly accelerated the trend towards healthcare modernisation, and we believe any product or service that brings efficiency to healthcare systems will be highly sought after. As big tech companies like Google, Amazon and Microsoft look to enter the health tech space, companies with an early-mover advantage should thrive or become takeover targets in their own right.
[Memo Assessment - 22-Sep-2023]: Sentiment = Strong
We saw ONE develop an incredibly strong sales pipeline as a result of the pandemic as evidenced by its large number of RFP/RFIs which it is now in the process of converting into sales. We see this sales pipeline as indicative of the strength of the macro theme.
In addition, this sales pipeline grew as a result of nurse shortages in the US during the pandemic, which led hospitals to seek new ways of improving efficiency through the adoption of tech like ONE’s offering.
Our Big Bet for ONE
"ONE re-rates to a +$500M market cap as it converts its sales pipeline into signed contracts and/or attracts a takeover bid at a premium to its market value"
NOTE: our “Big Bet” is what we HOPE the ultimate success scenario looks like for this particular Investment over the long term (3+ years). There is no guarantee that our Big Bet will ever come true. There is a lot of work to be done, many risks involved, including development risk, country risk and commodity price risk - just some of which we list in our ONE Investment Memo.
Success will require a significant amount of luck. Past performance is not an indicator of future performance.
Why did we invest in ONE?
Proven tech, liked by customers
ONE is moving into the growth stage having proven out its tech products in a hard to enter sector (hospitals).
[Memo Assessment - 22-Sep-2023]: Grade = A
We see the Baxter International deal as evidence that ONE is firmly in the growth stage and has the big brother it needs to rapidly expand.The fact that the largest hospital bed supplier in the US wants to sell ONE’s products to its customers validates ONE’s value proposition.
$20M capital injection to fund rapid growth
ONE completed a capital raise late in 2021 and with a war chest to fund its growth we look forward to ONE becoming cash flow positive and quickly increasing the number of contracted beds it has in the US.
[Memo Assessment - 22-Sep-2023]: Grade = A
ONE secured $20M in a placement at ~27 cents. This placement caused minimal dilution to existing shareholders and funded the company’s growth through a rough bear market for small caps tech stocks.
Under promise, over deliver
ONE’s management team has delivered everything they said they would since we invested, so we are confident they will hit their revenue projections and US market share objectives in 2022.
[Memo Assessment - 22-Sep-2023]: Grade = A
ONE introduced its Bring Your Own Device (“BYOD”) solution over the course of this Investment Memo which was a major positive surprise. ONE did very well at delivering in this regard.
What do we expect ONE to deliver?
Objective #1: Fast revenue growth and contracted beds in excess of 15,000
For ONE, ‘contracted beds’ is like an ‘active user’ metric for a tech company. We think this will be the basis for judging ONE’s success in 2022. More contracted beds = more revenue. We want to see ONE hit a total of 15,000 in 2022, primarily out of the USA.
[Memo Assessment - 22-Sep-2023]: Grade = A
While ONE took an extra quarter to deliver on this metric, we think it made significant progress in the US market and is now primed for more growth via the Baxter International value added reseller agreement.
Objective #2: Increased sales/marketing spend leading to more deals with major hospital networks
ONE now has a proven tech product that is valued by its clients. As of this memo, ONE spent less than 10% of its receipts from customers on advertising and marketing - if its to quickly accelerate contracted beds (revenue), we think upping spend in this area is crucial.
[Memo Assessment - 22-Sep-2023]: Grade = A
While following the 2022 $20M capital raise ONE did increase sales/marketing spend which played a big role in driving its sales pipeline, ONE had to subsequently reign in its sales/marketing spend as the 2022 tech wreck played out on the markets.
Although this wasn’t exactly what we wanted to see when we wrote our Investment Memo, we think that the pivot was a prudent move given the market conditions.
That is why we gave them an A for this Objective.
Objective #3: More sales through Microsoft and Samsung partnerships
As Samsung tablets are the device which works with the ONE product - Samsung sales reps should be incentivised to push ONE’s product. Likewise, since Microsoft’s Azure Marketplace is the cloud platform that ONE has opted to work with, we would like to see sales growth through this channel.
[Memo Assessment - 22-Sep-2023]: Grade = C
It does not appear that partnerships delivered significant value for ONE (yet), but could still prove valuable in the future. We have now added “Distribution Risk” to our next memo to highlight some of the challenges of leveraging a third party to drive sales for the company.
Objective #4: Material contribution to revenue from upsells to older coaxial wired hospitals wings
ONE is now providing “coaxial set-top boxes” which allow older hospital rooms that are wired up using legacy coaxial cables to use ONE (where previously they couldn’t) - we we want to see a wave of sign-ons of older hospital rooms that previously couldn’t use ONE, enough to materially impact topline revenue.
[Memo Assessment - 22-Sep-2023]: Grade = A
These coax setups helped ONE secure additional business and revenue over the course of this IM and will continue to help ONE get its platform into more hospitals.
What could go wrong?
Sales risk
Despite a strong customer retention rate and the endorsement of the product by prestigious hospitals, ONE could lose key clients or not seal as many deals in the coming 12 months, hurting their revenue and share price.
[Memo Assessment - 22-Sep-2023]: Risk = Decreased
ONE’s deal with Baxter International has potentially decreased sales risk as ONE now has a clear avenue to significant market penetration and will potentially have to do less leg work with Baxter helping drive sales.
Competition risk
ONE has an early mover advantage, but it is not alone in the space it operates in. We think ONE has a really powerful product that should be helped by its traction at some of the most prestigious hospitals in the US. That being said, a big tech company could launch a competitor product.
[Memo Assessment - 22-Sep-2023]: Risk = Decreased
ONE continued to develop its product “moat” by investing in new innovations and technologies that will reduce risk from other competitors in the market - in particular the launch of its BYOD solution.
Since this memo ONE has entered at least 5 new hospitals.
Given how slow hospitals are to adopt new technologies, each new hospital partner reduces the competition risk for ONE.
Funding risk
Although ONE raised $20M in November 2021, growth companies need cash to achieve their goals. If ONE doesn’t use the money from this raise wisely, then share price pain could follow. This was ONE’s third capital raise since it listed in 2016.
[Memo Assessment - 22-Sep-2023]: Risk = Decreased
ONE completed another $20M placement in July and an oversubscribed SPP at 18c. We see this as providing a great runway for the company as it approaches operating cash flow positive status.
Technology risk
ONE will need to add functionality to its products over time as the health tech industry advances. ONE has flagged that a range of additional features are in the pipeline, and the successful roll out of these features could help it reduce this particular risk as hospitals become more advanced.
[Memo Assessment - 22-Sep-2023]: Risk = Decreased
ONE is rapidly improving its offering, not least of which is its BYOD solution. We also believe ONE will be able to take advantage of AI more in the future to build out its offering and extend the capabilities of what is already a highly valuable product. AI could mean more features and less overheads on product development.
What is our investment plan?
We have invested in ONE twice since we announced it as our Tech Pick of the Year for 2021 in March last year.
The first time at 6 cents and the second time in the recent cap raise at 27 cents.
ONE experienced a significant share price re-rate during 2021 after it announced several new contracts and the health tech sector became hot. As per our usual investment plan we partially de-risked our position selling 22.37% of our total holding, achieving a partial free carry.
We plan to hold a position in ONE for the next 3-5 years (and beyond) as it progresses its plan to gain significant market penetration in the lucrative US healthcare market, and may look to take some profit by selling up to ~17% of our holding if the company successfully delivers on the key objectives listed above and the share price hopefully re-rates again.
[Memo Assessment - 22-Sep-2023]: Grade = A
During the memo we sold around ~15% of our Total Holdings, in line with what we planned. We also increased our Investment at the 18c placement price.
Disclosure: The authors of this memo and owners of Next Investors, S3 Consortium Pty Ltd, and associated entities, own 8,525,000 ONE shares at the time of writing. S3 Consortium Pty Ltd has been engaged by ONE to share our commentary on the progress of our investment in ONE over time.
ONE: Med Tech into 18 new US hospitals and a sales pipeline of ~€53M in potential recurring revenue.
Mar 16, 2026
Mar 16, 2026 |
26 min
We just took a pretty big swing (by our standards) into ASX listed medical tech company Oneview Healthcare (ASX: ONE)’s just announced $19M capital raise (at 19c).
ONE: share price going up - is this why?
Jan 23, 2026
Jan 23, 2026 |
12 min
Looks like the market likes what our medical-tech Investment OneView Healthcare (ASX:ONE) has been cooking up over the last couple of months. ONE’s share price has moved from a low of 16.5c in late October to ~40c now.
ONE: Results are in - Share price is up.
Feb 28, 2025
Feb 28, 2025 |
11 min
The results are in. Sales up, revenues up. Share price moving up… Is an inflection point coming for our health technology Investment OneView Healthcare (ASX: ONE)?
US$18BN Baxter extends US reseller deal with ONE, expands to Canada.
Oct 28, 2024
Oct 28, 2024 |
14 min
Today our health tech Investment and 2021 Tech Pick of the Year, Oneview Healthcare (ASX: ONE) released its quarterly report.
First deal for ONE’s new mobile product. Baxter relationship now "Internet official".
Sep 26, 2024
Sep 26, 2024 |
9 min
Two things we have noticed from our health tech Investment and 2021 Tech Pick of the Year, Oneview Healthcare (ASX: ONE) over the last week… And neither have been announced to the ASX…
ONE now available to an additional 85 hospitals across 15,000 hospital beds
Jan 16, 2026
Jan 16, 2026 |
3 min
Our medtech Investment Oneview Healthcare (ASX: ONE) just put out its December quarterly report.
ONE - our key takeaways from the AGM address
Dec 3, 2025
Dec 3, 2025 |
3 min
Our health tech Investment Oneview (ASX: ONE) was trading up as much as ~10% yesterday and is currently up again today following positive comments from the CEO at the AGM on Monday.
ONE appoints healthcare veteran Michael Dowling as director
Nov 13, 2025
Nov 13, 2025 |
3 min
Our health tech Investment Oneview (ASX: ONE) just appointed Michael Dowling to its board of directors.
ONE sales pipeline grows to 180+ opportunities
Oct 30, 2025
Oct 30, 2025 |
3 min
Our health tech Investment Oneview (ASX: ONE), just released its Q3 quarterly report.
ONE achieves important certification milestone for AI virtual assistant
May 12, 2025
May 12, 2025 |
4 min
Our Healthtech Investment OneView Healthcare (ASX: ONE) just received ISO 42001 certification - making it one of the first on the ASX to receive this certification. The certification is for ONE’s Virtual AI Assistant product.
Sunday Edition: 22nd March
Mar 22, 2026
Mar 22, 2026 |
22 min
Here you can find links to everything we wrote last week, plus some interesting stuff we came across on our travels.
Sunday Edition: 8th March
Mar 8, 2026
Mar 8, 2026 |
21 min
Here you can find everything we wrote about last week, plus some interesting stuff we came across on our travels. On Friday afternoon after market, the S&P Dow Jones Indices announced changes to the ASX indices, which will be effective from Monday March 23rd. A few of our Portfolio Stocks are climbing into the All Ordinaries Index...
Sunday Edition: 15th February
Feb 15, 2026
Feb 15, 2026 |
18 min
Here you can find everything we wrote about last week, plus some interesting stuff we came across on our travels.
Sunday Edition: 8th February
Feb 8, 2026
Feb 8, 2026 |
19 min
Here you can find everything we wrote about in the past week, plus some interesting stuff we came across on our travels. A much bigger week for announcements this week, we did quite a few QuickTakes so it appears companies are now well and truly back into the swing of things. Plus check out our new Investment: BMG
Sunday Edition: 25th January
Jan 25, 2026
Jan 25, 2026 |
21 min
Silver closed out the week at US$103. Up 7.3% in Friday’s session, and up ~43% in the first 24 days of January... Yesterday we wrote about legendary silver investor Eric Sprott. And how he had been buying more NASDAQ listed Hycroft Mining shares… even though it’s already almost up 1,000% from his initial entry price a few months ago. Another silver stock Eric Sprott has been buying on market in the last two weeks that hasn’t had a big run yet is our Investment Rapid Critical Metals (ASX: RCM). Read on for what we wrote about this week.
